IL6 and breast carcinoma: Although decreased expression of ER, increased circulating interleukin 6 (IL6) levels and the presence of circulating CSCs have independently been associated with metastatic progression in breast cancer patients11, 12, 13, no models have been proposed to explain their role in endocrine-resistant disease.